Peer-reviewed publication advances understanding of Fontan-associated liver disease (FALD) and adds to the growing body of evidence supporting udenafil in Fontan circulation FORT LEE, N.J., July 16, 2026 /PRNewswire/ -- Mezzion Pharmaceuticals today announced publication of "The FUEL FALD Study: Effects of Udenafil on Liver Stiffness and Fibrosis after Fontan" in the peer-reviewed journal Pediatric Cardiology. The publication reports findings from an exploratory substudy of the FUEL Open Label E

国家药监局数据显示，2026年上半年中国创新药对外授权共达成81笔合作，交易总额约1100亿美元，已达2025年全年总额的80%，交易覆盖肿瘤、代谢、免疫、神经等十大治疗领域，受让企业来自美国、英国、法国、意大利等20余个国家和地区。 从2016年不足10亿美元的License-out交易总额，到2025年的超千亿美元，中国创新药用了不到十年时间，完成了一场从全球医药价值链“边缘参与者”向“核心竞逐者”的身份转换。 然而，这场波澜壮阔的出海浪潮，绝不仅仅是“量”的碾压式胜利。比交易金额更值得关注的，是出海模式的深层变革。 这一系列变革背后，是全球医药市场结构性重塑与“中国创新加速度”的必然碰撞。2030年前，全球将有超过3000亿美元销售额的药物失去专利保护，跨国药企面临史上最严峻的“专利悬崖”。 与此同时，中国创新药在ADC药物管线中的全球占比已超过40%，在CAR-T临床研究项目中的登记数量与美国并驾齐驱——中国不再是简单的“仿制大国”，而是正在成为ADC、双抗、CGT等前沿领域的全球创新策源地。 然而，盛宴之下，暗流涌动。当BD从稀缺事件变为常态，简单的授权故事已不足以支撑估值。

当AI从宏大叙事沉入行业毛细血管，大健康赛道的玩家们站在了同一条河流的不同岸上，少数企业已将AI锻造成组织级的战略引擎，而多数仍在零散的试点中摸索前行。345份真实问卷背后，是一场关于战略远见、组织变革与人才争夺的深层较量。 撰文｜廖晓琴 2026年刚过半，英矽智能已连续拿下施维雅、礼来、SK生物制药、武田制药等多家药企的BD合作，潜在交易总价值逼近70亿美元，上半年预计营收突破1亿美元，首次实现扭亏为盈。这个曾被行业怀疑“AI制药到底能不能赚钱”的明星公司，正在用密集的BD交易，让行业重新审视药企AI转型的商业价值。 虽然人人都在谈论AI，但并非所有企业都站在同一条起跑线上。办公室里，销售代表对着电脑输入客户信息，等待AI生成一份拜访纪要；实验室里，研究员借助算法筛选化合物，试图缩短漫长的药物发现周期。但这幅看似火热的图景之下，一个更本质的问题正在浮现：AI究竟是被当作一把顺手的新工具，还是正在重塑整个组织的基因？ 不少企业有着更为具体的疑问，同行的AI实践进展如何？有哪些已经跑通的商业化路径？关键岗位和人才画像变了，HR和业务负责人该如何应对？如何让AI不止是个工具，而成为组织级能

CRO的众生相，向来是医药行业最真实的晴雨表。如今，眼泪已在时代中飞去，我们正见证下一个浪潮的来临。 撰文｜张烨静 随着2026年H1业绩预告陆续出炉，CRO们让市场坐了一回“过山车”。 一边是以昭衍新药为代表的“猴茅”因实验猴资产增值而业绩暴涨，另一边是阳光诺和等仿制药CRO深陷亏损泥潭；而康龙化成等头部CRO则因创新药的繁荣进入“黄金时代”。 7月14日晚间，昭衍新药公告，预计2026年半年度归母净利润为6亿元至9亿元，同比增长884.9%至1377.4%。“猴茅”神话仍在续写，但光环之下，其实验室服务及其他业务净利润仅为-1.42亿元至0.65亿元，主业仍徘徊在亏损或微利边缘。 次日，曾经的仿制药CRO阳光诺和发布公告，上半年归母净利润预计亏损1497万至2994万元，较上年同期减少约1.44亿至1.60亿元，降幅高达111.53%至123.06%。 事实上，仿制药CRO的惨烈远不止于此。过去半年多，行业里死伤遍地、卖身求生、亏损连连。百诚医药连亏两年，卖身未果；南京诺和欣医药正式注销；百花医药、则正医药业绩大幅滑坡，最终由国资接盘。一批CRO试图从仿制转向创新，但新旧动能转换之

New handheld robotic technology expands the Mako platform and brings Mako robotic-assisted knee replacement to a new segment of the orthopaedic market Stryker announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement procedures. The launch introduces Mako Handheld Robotics, expanding the Mako portfolio beyond robotic-arm assisted surgery. Mako RPS combines robotic execution, intraoperative planning and a familiar handheld power tool workflow. PORTAGE,

SALT LAKE CITY, July 16, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of Wes Lindsey, PhD, MBA as the Company's new Chief Scientific Officer ("CSO"). Dr. Lindsey brings more than 20 years' experience in molecular diagnostics. He holds a PhD in Genetics & Molecular Biology from Emory University and an MBA from

RALEIGH, N.C., July 16, 2026 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc., a specialty pharmaceutical company advancing the science of testosterone therapy and hormone health, today welcomed Defense Secretary Pete Hegseth's announcement that the Department of Defense will begin annually screening service members age 30 and older for testosterone deficiency, with optional screening available to younger troops. The program, which will be incorporated into the military's existing periodic hea

MENLO PARK, Calif., July 16, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a collaboration with Priority Health, a nationally recognized nonprofit health plan and the third largest provider-sponsored health plan in the nation, to make GRAIL's Galleri® multi-cancer early detection (MCED) test available to Priority Health's self-insured employer groups. Priority Health launched coverage for Galler

Funding to accelerate U.S., European and Middle East commercialization and collect clinical evidence for U.S. weight loss marketing indication GOSSELIES, Belgium, July 16, 2026 /PRNewswire/ -- Endo Tools Therapeutics (ETT), developers of advanced endoscopic medical devices, today announced the closing of its Series C financing round, raising € 20 million (c. $ 23 million) to advance U.S., European and Middle East commercialization of the endomina® platform, including the recently FDA-cleared end

ACLM applauds CMS' proposed changes that emphasize chronic disease prevention, behavioral health, and transformation of primary care for Medicare beneficiaries. ST. LOUIS, July 16, 2026 /PRNewswire/ -- The American College of Lifestyle Medicine (ACLM) welcomes the Centers for Medicare and Medicaid Services' (CMS) Physician Fee Schedule proposed rule announced yesterday, which includes long-awaited provisions that can provide greater access to lifestyle medicine for Medicare beneficiaries and imp